前列腺癌
癌症研究
表皮生长因子
MAPK/ERK通路
内分泌学
前列腺
内科学
血管紧张素II
雄激素受体
生物
医学
癌症
信号转导
受体
细胞生物学
作者
Hiroji Uemura,Hitoshi Ishiguro,Noboru Nakaigawa,Yoji Nagashima,Yasuhide Miyoshi,Kiyoshi Fujinami,Akihiro Sakaguchi,Yoshinobu Kubota
出处
期刊:PubMed
日期:2003-11-01
卷期号:2 (11): 1139-47
被引量:56
摘要
Angiotensin II (A-II) receptor (AT(1) receptor) blockers (ARB) are a class of antihypertensive agent. It is known that they suppress signal transduction pathways mediated by growth factors [e.g., epidermal growth factor (EGF)] through the AT(1) receptor in vascular endothelial cells. In the present study, we demonstrated that A-II activates the cell proliferation of prostate cancer as well as EGF. In addition, we showed that A-II induces the phosphorylations of mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription 3 (STAT3) in prostate cancer cells. In contrast, ARB was shown to inhibit the proliferation of prostate cancer cells stimulated with EGF or A-II, the mechanism of which is through the suppression of MAPK or STAT3 phosphorylation by ARB. Oral administration of ARB to nude mice inhibited the growth of prostate cancer xenografts in both androgen-dependent and androgen-independent cells in a dose-dependent manner. Microvessel density was reduced in xenografts treated with ARB, which means ARB inhibits the vascularization of xenografts. Expression of AT(1) receptor mRNA was examined by reverse transcription-PCR using 10 pairs of human prostate cancer and normal prostate tissues. AT(1) receptor expression in human prostate cancer tissue was higher (9 of 10 cases) than that in normal prostate tissue. These results suggest the possibility that ARB is a novel therapeutic class of agents for prostate cancer, especially hormone-independent tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI